Pfizer and TheCUBE team up to launch InnomakersLAB, a hub through which they seek to respond to the needs of the health sector through innovation.
InnomakersLAB is the proposal with which Pfizer and TheCUBE seek to take advantage of the possibilities offered by innovation to the health sector. Located in the facilities of TheCUBE Madrid, this space will enjoy the resources of the THECUBE ecosystem and will have different acceleration programs and the support of expert mentors in the development of health projects.
The purpose is to take advantage of the possibilities offered by an environment like this hub for the development of ideas, from their conception to their execution, with a meticulous follow-up by both companies to help give life to the projects of the teams that enter it.
Among some of the programs to be taught, it is worth highlighting the training of Acceleration Program, a program designed to define, prototype and develop an MVP (Most Valuable Project) and to which the winners of Innomakers4Health will be able to access, the program created by both companies to respond to the most relevant challenges in the health sector.
From this space, the winners of this program have the possibility of implementing and executing their winning project generating a real impact on people’s lives.
Another of the strengths of this hub is the training that participants will receive through Mentorship Programs with sessions on innovation, business and technology, taught by experts from TheCUBE and the ecosystem to help Pfizer teams develop their ideas and projects.
Support for innovation in the health sector
Not only Innomarkers4Health winners will have access to InnomakersLAB. Teams and startups selected by Pfizer will also be able to attend the hub and will be able to access all the tools available in this space to advance their projects.
With this they will be able to benefit from the possibilities offered by both companies. On the one hand, TheCUBE, an ecosystem of innovation and entrepreneurship, which has the experience and resources necessary to promote the selected proposals.
For this, it has startups, the MIOTI school, experts in business related to innovation and technology, exploration centers of large corporations such as the “2122 LAB” of the Pelayo company or the Enel Innovation Hub Europe, among others.
This alliance also highlights Pfizer’s interest in supporting the community of innovative in the field of health that contribute to change the lives of patients.
